ATE170082T1 - Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen - Google Patents

Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen

Info

Publication number
ATE170082T1
ATE170082T1 AT95117465T AT95117465T ATE170082T1 AT E170082 T1 ATE170082 T1 AT E170082T1 AT 95117465 T AT95117465 T AT 95117465T AT 95117465 T AT95117465 T AT 95117465T AT E170082 T1 ATE170082 T1 AT E170082T1
Authority
AT
Austria
Prior art keywords
protein
growth
inhibiting
cells
leukemic cells
Prior art date
Application number
AT95117465T
Other languages
English (en)
Inventor
Hans-Joerg Dr Buehring
Original Assignee
Univ Eberhard Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Eberhard Karls filed Critical Univ Eberhard Karls
Application granted granted Critical
Publication of ATE170082T1 publication Critical patent/ATE170082T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95117465T 1994-11-10 1995-11-07 Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen ATE170082T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33760594A 1994-11-10 1994-11-10

Publications (1)

Publication Number Publication Date
ATE170082T1 true ATE170082T1 (de) 1998-09-15

Family

ID=23321225

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95117465T ATE170082T1 (de) 1994-11-10 1995-11-07 Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen

Country Status (3)

Country Link
EP (1) EP0711565B1 (de)
AT (1) ATE170082T1 (de)
DE (1) DE69504278T2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
AU7710300A (en) * 1999-09-22 2001-04-24 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
WO2002013847A2 (en) * 2000-08-14 2002-02-21 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (de) 2005-02-23 2013-10-16 Genentech, Inc. Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010051502A2 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Also Published As

Publication number Publication date
EP0711565B1 (de) 1998-08-26
EP0711565A1 (de) 1996-05-15
DE69504278D1 (de) 1998-10-01
DE69504278T2 (de) 1999-05-06

Similar Documents

Publication Publication Date Title
ATE170082T1 (de) Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen
DE60330390D1 (de) G-csf zur behandlung von amyotropher lateralsklerose
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69508192D1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69809898D1 (de) Zusammensetzung und verfahren zur behandlung von pflanzen mit exogenen chemikalien
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
TW200502385A (en) Modulation of forkhead box o1a expression
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
DE69622989D1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE298246T1 (de) Aktiviertes protein c zur behandlung von pankreatitis
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
ATE331799T1 (de) Verfahren zur inhibierung der transkription von genen
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE203162T1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
ATE227696T1 (de) Vorrichtung zur behandlung von wasser
DE69936234D1 (de) Verfahren und Zusammenstzung zur Hemmung des Wachtums von neoplastischen Zellen
DE60022549D1 (de) Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee